Table 4 Clinical data of included studies for the efficacy of antiviral treatment on all-cause and liver-specific mortality in patients with CHC
Study | Nationality | Age | Duration of follow up | Study format | Genotype | NOS | Treatment | Death/Total treatment | Death/Control | Histology |
|---|---|---|---|---|---|---|---|---|---|---|
Benvegnù L et al. (1998) [27] | Italy | Tx: 56.7, control: 59.5 (mean) | mean 71.5 months | P | unknown | 8 | IFN | a3/75 | a15/77 | Child A LC |
Ikeda K et al. (2001) [33] | Japan | 57 (median) | median 7.6 years | R | unknown | 7 | IFN-α or IFN-β | 20/113 a12/113 | 266/581 a124/581 | LC |
Gramenzi A et al. (2001) [34] | Italy | Tx: 57.9, control: 58.1 (mean) | median 55–58 months | P | unknown | 7 | IFN-α | a7/72 | 9/72 a8/72 | LC (mainly Child A) |
Nishiguchi S et al. (2001) [35] | Japan | Tx: 54.7, control: 57.3 (mean) | mean 8.2 years | RCT | 75.6% type 2 |  | IFN-α | 5/45 | 26/45 | unknown |
Testino G et al. (2002) [16] | Italy | Tx: 55.3, control: 56.8 (mean) | mean 95.4 months | R | 55% type 1b, 45% type 2 | 8 | IFN-α | 1/51 | 9/71 | Child A LC |
Yosida H et al. (2002) [47] | Japan | Tx: 49.5, control: 54.6 (mean) | mean 5.4 years | R | unknown | 8 | IFN-α or IFN-β | 56/2430 a35/2430 | 30/459 a23/459 | F3,4: 32.2% in Tx, 31.6% in control, 26.3% in SVR, 35.2% in no SVR |
Imazeki F et al. (2003) [48] | Japan | Tx: 49.2, control: 53.1 (mean) | mean 8.2 years | R | 73.9% type 1 | 8 | IFN-α or IFN-β | 33/355 a19/355 | 15/104 a12/104 | F3,4: 26.7% in Tx, 29.8% in control, |
Coverdale SA et al. (2004) [36] | Australia | Tx: 37, control: 38 (median) | median 9 years | P | 39.6% type 1 | 7 | IFN-α | a36/384 | a12/71 | Scheuer fibrosis score 2 |
Kasahara A et al. (2004) [17] | Japan | Tx: 53, control: 54 (median) | mean 6Â years | R | unknown | 8 | IFN | 101/2698 a69/2698 | 52/256 a42/256 | F3,4: 38.7% in Tx, 48% in control, 28.6% in SVR, 43% in no SVR |
Shiratori Y et al. (2005) [38] | Japan | Tx: 57, control: 61 (median) | median 6.8 years | P | 71.9% type 1b | 8 | IFN-α or lymphoblastoid | 45/271 a32/271 | 24/74 a19/74 | unknown |
Yu ML et al. (2006) [39] | Taiwan | Tx: 46.9, control: 43.6 (mean) | mean 5.18–5.15 years | R | 46.2% type 1 | 8 | IFN-α with or without RBV | 16/1057 a14/1057 | 12/562 a10/562 | LC 15.6% in Tx, 12.1% in control |
Di Martino V et al. (2011) [41] | France | unknown | median 59Â months | R | 57.9% type 1 | 7 | IFN with or without RBV, or PegIFN with RBV | 9/184 a5/184 | 20/194 a4/184 | 55.5%Â F2 or greater |
Yamasaki K et al. (2012) [49] | Japan | 60.9 (mean) | median 11.5 years | P | 59.9% type 1b | 7 | IFN-α or β or lymphoblastoid with or without RBV | 25/152 a6/152 | 90/199 a32/199 | unknown |
Maruoka D et al. (2012) [43] | Japan | 50.4–54 (mean) | mean 9.9 years | R | 73.6% type 1 | 8 | IFN-α/IFN-β with or without RBV | 84/577 a52/577 | 37/144 a30/144 | F3,4: 24.3% in Tx, F4: 43.1% in control |
Cozen ML et al. (2013) [44] | US | 50.98 (mean) | mean 10 years | R | 68.7% type 1 | 8 | IFN-α with or without RBV | 31/159 | 47/199 | F3,4: 19% (30.2% in Tx, 10.1% in control) |
Aleman S et al. (2013) [45] | Sweden | 51 (mean) | mean 5.3Â years | R | 50% type 1 | 8 | PegIFN with RBV | 59/303 a39/303 | 18/48 a16/48 | LC |
Kutala BK et al. (2015) [50] | France | 50 (median) | median 5.5Â years | R | 55.7% type 1 | 8 | IFN/PegIFN with or without RBV | 30/325 | 19/102 | F3,4: 100% |
Cozen ML et al. (2016) [46] | US | 51.4 (mean) | mean 8.5 years | P | 71.6% type 1 or 4 | 8 | IFN-α with RBV | 112/692 | 488/1519 | LC 15.8% in Tx, 5.3% in control |